Pterygium Clinical Trial
Official title:
Study of the Safety and Effectiveness of the Ologen(OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery
The purpose of this study is to determine whether the ologen (OculusGen) Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery and pterygium excision surgery.
ologen (OculusGen) Collagen Matrix is a porous, scaffold matrix. It is to be implanted on the top of the scleral flap and beneath the conjunctiva and Tenon's capsule at the end of trabeculectomy. The pores in the scaffold matrix range from 20 to 200µm, a size that is suitable for fibroblasts to grow randomly, through the body of the matrix without causing scarring. The space occupied by the collagen matrix scaffold creates room for the development of a filtration bleb. Immediately after implantation, the collagen matrix is absorbed with the aqueous humor that bring a certain pressure press on the top of scleral flap which makes the dynamic balance for the aqueous system to keep the IOP in the right side. The collagen matrix is bio-degraded within 90 days and will leave a physiologic space for the filtration bleb to facilitate control of intraocular pressure (IOP). ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02641132 -
Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.
|
Phase 4 | |
| Completed |
NCT02342392 -
Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01387971 -
Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders
|
N/A | |
| Recruiting |
NCT05978687 -
The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision
|
Phase 4 | |
| Not yet recruiting |
NCT06042296 -
Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
|
||
| Completed |
NCT04022811 -
Effect of Bromfenac on Pain Related to Pterygium Surgery
|
Phase 4 | |
| Recruiting |
NCT01249235 -
Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery
|
N/A | |
| Recruiting |
NCT01261455 -
Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia
|
N/A | |
| Completed |
NCT01115517 -
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
|
Phase 2 | |
| Completed |
NCT00768963 -
Ranibizumab for the Inhibition of Neovascularization in Pterygia
|
Phase 1 | |
| Completed |
NCT00949728 -
Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia
|
N/A | |
| Recruiting |
NCT00563277 -
Surgical Treatment of Concurrent Cataract and Primary Pterygium
|
N/A | |
| Completed |
NCT00346450 -
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
|
Phase 3 | |
| Completed |
NCT03533244 -
A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
|
Phase 2 | |
| Completed |
NCT04403516 -
Dextenza in Pterygium Surgery
|
Phase 4 | |
| Recruiting |
NCT02911532 -
Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia
|
N/A | |
| Not yet recruiting |
NCT03304366 -
Corneal Changes With Pentacam Before and After Pterygium
|
N/A | |
| Unknown status |
NCT02015000 -
Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation
|
N/A | |
| Completed |
NCT00344201 -
Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery
|
Phase 1 | |
| Recruiting |
NCT00326560 -
Comparison of Glue With Sutures for Pterygium Surgery
|
Phase 3 |